MF59 adjuvant: the best insurance against influenza strain diversity

This publication has 91 references indexed in Scilit:

• Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development
  Proceedings of the National Academy of Sciences, 2010
• Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
  New England Journal of Medicine, 2009
• Response to a Monovalent 2009 Influenza A (H1N1) Vaccine
  New England Journal of Medicine, 2009
• Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages
  Vaccine, 2009
• Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
  Proceedings of the National Academy of Sciences, 2009
• Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets
  Vaccine, 2009
• Adjuvanted H5N1 vaccine induces early CD4⁺T cell response that predicts long-term persistence of protective antibody levels
  Proceedings of the National Academy of Sciences, 2009
• Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses
  Nature Structural & Molecular Biology, 2009
• Molecular and cellular signatures of human vaccine adjuvants
  Proceedings of the National Academy of Sciences, 2008
• The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine
  Vaccine, 2007